Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. more
Time Frame | BMY | Sector | S&P500; |
---|---|---|---|
1-Week Return | 1.35% | - | - |
1-Month Return | -4.44% | -4.69% | -4.31% |
3-Month Return | -1.22% | -0.01% | 2.99% |
6-Month Return | -11.34% | 8.95% | 16.99% |
1-Year Return | -26.95% | 5.44% | 21.41% |
3-Year Return | -17.22% | 19.83% | 24.84% |
5-Year Return | 27.87% | 76.19% | 85.4% |
10-Year Return | 30.68% | 183.6% | 218.97% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 26.14B | 42.52B | 46.38B | 46.16B | 45.01B | [{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":91.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.51,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}] |
Cost of Revenue | 8.08B | 11.77B | 9.94B | 10.14B | 10.69B | [{"date":"2019-12-31","value":68.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.43,"profit":true},{"date":"2022-12-31","value":86.1,"profit":true},{"date":"2023-12-31","value":90.83,"profit":true}] |
Gross Profit | 18.07B | 30.75B | 36.45B | 36.02B | 34.31B | [{"date":"2019-12-31","value":49.57,"profit":true},{"date":"2020-12-31","value":84.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.84,"profit":true},{"date":"2023-12-31","value":94.15,"profit":true}] |
Gross Margin | 69.10% | 72.31% | 78.57% | 78.04% | 76.24% | [{"date":"2019-12-31","value":87.95,"profit":true},{"date":"2020-12-31","value":92.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.32,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}] |
Operating Expenses | 12.15B | 28.57B | 27.91B | 26.92B | 26.12B | [{"date":"2019-12-31","value":42.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.69,"profit":true},{"date":"2022-12-31","value":94.22,"profit":true},{"date":"2023-12-31","value":91.42,"profit":true}] |
Operating Income | 5.46B | 5.13B | 10.16B | 10.33B | 17.24B | [{"date":"2019-12-31","value":31.69,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":58.92,"profit":true},{"date":"2022-12-31","value":59.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (1.15B) | (13.42B) | (3.40B) | (3.85B) | 267.00M | [{"date":"2019-12-31","value":-428.84,"profit":false},{"date":"2020-12-31","value":-5025.84,"profit":false},{"date":"2021-12-31","value":-1271.54,"profit":false},{"date":"2022-12-31","value":-1440.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 4.97B | (6.87B) | 8.10B | 7.71B | 8.44B | [{"date":"2019-12-31","value":58.95,"profit":true},{"date":"2020-12-31","value":-81.41,"profit":false},{"date":"2021-12-31","value":95.95,"profit":true},{"date":"2022-12-31","value":91.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 1.51B | 2.12B | 1.08B | 1.37B | 400.00M | [{"date":"2019-12-31","value":71.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.04,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":18.83,"profit":true}] |
Income After Taxes | 3.46B | (8.99B) | 7.01B | 6.34B | 8.04B | [{"date":"2019-12-31","value":43.03,"profit":true},{"date":"2020-12-31","value":-111.88,"profit":false},{"date":"2021-12-31","value":87.24,"profit":true},{"date":"2022-12-31","value":78.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 6.49B | (8.99B) | 7.01B | 6.34B | 8.30B | [{"date":"2019-12-31","value":78.16,"profit":true},{"date":"2020-12-31","value":-108.33,"profit":false},{"date":"2021-12-31","value":84.48,"profit":true},{"date":"2022-12-31","value":76.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 3.44B | (8.99B) | 6.99B | 6.33B | 8.03B | [{"date":"2019-12-31","value":42.85,"profit":true},{"date":"2020-12-31","value":-112.09,"profit":false},{"date":"2021-12-31","value":87.15,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 4.67 | 6.44 | 7.50 | 7.80 | 7.50 | [{"date":"2019-12-31","value":59.87,"profit":true},{"date":"2020-12-31","value":82.56,"profit":true},{"date":"2021-12-31","value":96.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.15,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BMY | |
---|---|
Cash Ratio | 0.55 |
Current Ratio | 1.43 |
Quick Ratio | 1.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BMY | |
---|---|
ROA (LTM) | 5.63% |
ROE (LTM) | 26.53% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BMY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.69 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.31 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 3.23 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BMY | |
---|---|
Trailing PE | 12.68 |
Forward PE | 6.93 |
P/S (TTM) | 2.17 |
P/B | 3.32 |
Price/FCF | 25 |
EV/R | 2.82 |
EV/Ebitda | 6.56 |
PEG | 0.40 |
With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellares kdunleavy Mon, 04/22/2024 - 10:44
In February, I recommended five one-month momentum plays to buy as Bitcoin ( BTC-USD ) prices surged. The world’s largest cryptocurrency is a surprisingly good gauge of bubbly investor sentiment, and our writers at InvestorPlace.com had found several strong candidates to ride the market higher. Over the following month, these picks would rocket 47%, on average. Even assets with relatively weak fundamentals will go up if investors are bullish enough. Ticker Name 18-Feb Price 18-Mar Price Change PLUG Plug Power $ 4.00 $3.30 -15.9% SOUN SoundHoundAI $3.80 $8.90 133.2% NVDA Nvidia $726.10 $878.40 21.0% ETH Ethereum $2,881.30 $3,518.40 22.1% SOL-USD Solana $112.20 $196 74.7% Average Return 47.0% However, market sentiment has since soured. Bitcoin has lost 18% of its value since peaking in mid-March, and many smaller cryptocurrencies have fallen even further. There are other signs of growing market fear. On Monday, the CBOE Volatility Index (VIX) surged from its previous Friday low of $15 to over $19.50. (Since 2001, any time the VIX has risen more than 25% in a trading day, the market would go on to underperform its long-term average by an annualized 7.4% over the following 30 days).
Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Jetzt den vollständigen Artikel lesen
Nasdaq index gets creamed as high flyers take it on the chin Feds Financial Stability Report: Persistent inflation/tigher policy biggest risk Bank of Canada''s Macklem: Inflation is continuing to become less broad-based Crude oil futures settle at $82.22. What are the technicals telling traders. ECBs Muller: Sees a few more rate cuts by year end after June IMFs Japan Mission Chief: Weak yens impact on Japans economic growth is net positive BOEs Mann: Central banks will have to use autonomy effectively Baker Hughes oil rig count 511 vs 506 last week European indices close the week with mixed results IMF''s Georgieva: Need to finish the job on inflation ECB Wunsche: I dont have base case, but unlikely we cut only once in 2024 More from BOE Ramsden: We will take into account Forex implications for inflation More Goolsbee:There are some measures in the economy, that historically don''t portend well More Goolsbee: We have done great on the employment mandate but not on inflation Chicago Fed Pres.
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again. Inflation was moderating and the Federal Reserve was hinting it would cut interest rates at least three times this year. Beginning last October, the performance of the Russell 2000 index of small-cap stocks started pulling away from that of the S&P 500 . But it wouldn’t last. Runaway government spending drove inflation higher and Fed chairman Jay Powell just intoned he no longer has “confidence” inflation is heading the right way. That means we won’t get interest rate cuts until at least December, according to some analysts. High interest rates are death to small businesses. Because they rely upon financing to fund their expansion, a rising rate environment absolutely kills the small business market. It’s why the Russell 2000 has been such a poor performer these past few years. It could also mean they will continue lagging in 2024.
With key earnings being releases next week, the Nasdaq is flushing more to the downside. The NASDAQ index is now down -1.61% or -251 points at 15350.76.In the process, the price is running away from its 100 day moving average of 15489.71 and the 50% midpoint of the 2024 trading range at 15508.22. Bearish. Shares of Nvidia are breaking and falling away from the 50-day MA at 841.39. The price has not traded materially below the 50 day MA since November 2023. Next week, is pivotal with a number of large-cap stocks reporting including. Monday: Verizon SAP Tuesday: GM Tesla Visa Texas Instruments Wednesday: Boeing AT&T General Dynamics Meta Platforms IBM Ford Chipotle ServiceNow Thursday: American Airlines Caterpillar Southwest Airlines Bristol-Myers Squibb Microsoft Alphabet Intel Friday Exxon Mobil Chevron This article was written by Greg Michalowski at www.forexlive.com.
Bristol-Myers Squibb Company (BMY) share price today is $49.44
Yes, Indians can buy shares of Bristol-Myers Squibb Company (BMY) on Vested. To buy Bristol-Myers Squibb Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BMY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bristol-Myers Squibb Company (BMY) via the Vested app. You can start investing in Bristol-Myers Squibb Company (BMY) with a minimum investment of $1.
You can invest in shares of Bristol-Myers Squibb Company (BMY) via Vested in three simple steps:
The 52-week high price of Bristol-Myers Squibb Company (BMY) is $68.02. The 52-week low price of Bristol-Myers Squibb Company (BMY) is $47.03.
The price-to-earnings (P/E) ratio of Bristol-Myers Squibb Company (BMY) is 12.81
The price-to-book (P/B) ratio of Bristol-Myers Squibb Company (BMY) is 3.32
The dividend yield of Bristol-Myers Squibb Company (BMY) is 4.9%
The market capitalization of Bristol-Myers Squibb Company (BMY) is $100.20B
The stock symbol (or ticker) of Bristol-Myers Squibb Company is BMY